Key facts
- This page summarizes Vickie S. Reed's Form 4 filing for Mirati Therapeutics, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jan 2022, 19:34.
Vickie S. Reed - 14 Jan 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.
- Reporting relationship
- SVP, Chief Accounting Officer
- Issuer ticker
- N/A
- Reported as of
- 14 Jan 2022
- Net transaction value
- -$64,217
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2022, 19:34:06 UTC
- Prior SEC filing
- 07 Jan 2022
- Next SEC filing
- 28 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Gelfand, Attorney in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vickie S. Reed filed Form 4 for Mirati Therapeutics, Inc. on 18 Jan 2022.
Change
- Previous filing in this sequence was filed on 07 Jan 2022.
- Current net transaction value: -$64,217.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,377
- Change %
- +51%
- Price
- $0.000000
- Shares after
- 15,902
- Date
- 14 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
MRTX
transaction
Common Stock
Sale
- Transaction value
- $64,217
- Shares
- -533
- Change %
- -3.4%
- Price
- $120.48
- Shares after
- 15,369
- Date
- 18 Jan 2022
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRTX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,910
- Change %
- Price
- $0.000000
- Shares after
- 8,910
- Date
- 14 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,910
- Exercise price
- $124.31
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
Footnote F2
Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.
Footnote F3
The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.2091 to $120.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Footnote F4
25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.